This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

EfficacyEfficacyKey HighlightsEfficacyHospitalisation DataSafetySafetySafetyAdverse Event Management: VOD/SOSKey PrecautionsDosingDosingDosingAdministrationSupport and ResourcesSupport and ResourcesSupport and ResourcesGuidelinesFast FactsPharmacy GuidePatient SupportDevelopments in Leukaemia Care videoKey data from the INO-VATE study videoManagement of Refractory/Relapsed ALL videoMRD PubExplainer videoINO-VATE PubExplainer videoVideosMaterials

The content of this website has been produced in line with the BESPONSA® (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA Prescribing Information for Great Britain click here. BESPONSA Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Management of Refractory/Relapsed ALL videoSpeaker: Professor David Marks

Duration: 07:34

In this video, Professor Marks discusses the goals of treatment for relapsed/refractory acute lymphoblastic leukaemia patients in the INO-VATE study:​​​​​​​
  • Key outcomes from the INO-VATE1 study: BESPONSA vs. standard chemotherapy
  •  Long term follow up2
  • How to approach haematopoietic bone marrow transplant post BESPONSA
  •  Veno-occlusive disease risk analysis assessment before considering BESPONSA treatment
  • Reducing risks of veno-occlusive disease during treatment with BESPONSA

David Marks is Professor in Haematology and Stem Cell Transplantation and Director of
the Bristol Bone Marrow Transplant (BMT) Unit. He additionally holds an Honorary Senior Lectureship at the University of Bristol. He received his medical education at the University of Melbourne, Australia, and his clinical training at the Royal Melbourne Hospital, before undertaking positions in London, UK, and Philadelphia, PA, USA. He was appointed as a Consultant at the Bristol BMT Unit in 1996.

David’s research and scientific papers focus on clinical aspects of stem cell transplantation,
acute lymphoblastic leukaemia (ALL) and infection. In 1999, he worked to initiate the Clinical
Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT), the
first national transplant trial group. He chaired the group for 5 years and was President of
BSBMT from 2007 to 2009. From 2012 to 2015, he was European Vice Chair of the Advisory Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), and in 2017, he was the CIBMTR Chair of the Tandem BMT meetings in Orlando, FL, USA.
Since 2016, he has been Medical Director of IMPACT, the UK transplant trials platform. He is currently Transplant Coordinator and Deputy Chair of the National Cancer Research Institute ALL Working Group, Chair of the Adjudication Committee of BSBMT and a member of the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

He has authored numerous scientific papers and chaired the ALL education session at the American Society of Hematology meeting in 2010.

Explore more

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survivalLearn More Loading

Key data from the INO-VATE study

Hear Dr. Anna Castleton discuss the key data for BESPONSA vs standard care from the INO-VATE study

Learn More Loading

SmPC, Summary of product characteristics

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References:

Kantarjian HM, et al. New Engl J Med. 2016;375:740-53.Kantarjian HM, et al. Cancer 2019;125;2474–2487
PP-INO-GBR-0636. February 2022
Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

Sign up now Loading
​​​​​PP-PFE-GBR-2809. March 2021
Fast Facts

Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile. Summary of Product Characteristics (SmPC) should be consulted for full guidance.

Download here Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​